Drug intelligence / Profile preview

ASC36_35FDC

Development stage: Unknown
Lead developer: Ascletis Pharma
Modality: Peptides
Administration: Subcutaneous

Overview

ASC36_35FDC is a long-acting, once-monthly subcutaneous triple peptide agonist fixed-dose combination (FDC) being developed by Ascletis (歌礼生物科技) for the treatment of obesity. The drug acts as a triple agonist targeting the amylin receptor, glucagon-like peptide-1 receptor (GLP-1R), and glucose-dependent insulinotropic polypeptide receptor (GIPR). By simultaneously activating these three pathways, ASC36_35FDC aims to leverage synergistic effects on appetite suppression, glycemic control, and weight reduction. It is currently in the Discovery to Phase I stage of development.

Targets

AMY receptor (Calcitonin receptor (with ramps))GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)

Beyond the preview

Go deeper on ASC36_35FDC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASC36_35FDC.

Explore the full profile